If you have read a headline about weight-loss injections in the past couple of years, there is a good chance it mentioned Mounjaro. It has become one of the most talked-about medicines in the country, praised for results that were once only associated with surgery and scrutinised for the way it is bought and sold. But behind the hype, what actually is Mounjaro, how does it work inside the body, and what can it realistically do? Here is a clear, independent guide.
This article is educational only. Mounjaro is a prescription-only medicine, and whether it is right or safe for any individual is a decision for a suitably qualified prescriber — not something to self-diagnose or source online.
What is Mounjaro?
Mounjaro is the brand name for tirzepatide, a once-weekly injection developed by Eli Lilly and given under the skin of the abdomen, thigh or upper arm. It was first licensed for type 2 diabetes, and in November 2023 the UK medicines regulator, the MHRA, authorised it for weight management. It is the only dual GIP/GLP-1 receptor agonist currently licensed for weight loss in the UK, and at present it delivers the highest average weight loss of any approved anti-obesity medicine.
That word “dual” is the key to understanding why Mounjaro attracts so much attention. Most other weight-loss injections, including Ozempic and Wegovy, act on a single hormone pathway. Tirzepatide works on two at once — and to see why that matters, it helps to understand what these hormones do.
How does Mounjaro work? The dual-hormone mechanism
Mounjaro mimics two natural gut hormones called incretins, which your body releases when you eat. The better-known of the two is GLP-1 (glucagon-like peptide-1), produced in the small intestine. In its natural form it is broken down within a minute or two, but tirzepatide is engineered to keep working for around a week, which is why a single weekly dose is enough.
GLP-1 influences weight and blood sugar through several overlapping mechanisms:
- It reduces appetite. GLP-1 receptors sit on neurons in the hypothalamus, the part of the brain that governs hunger and fullness. Activating them dials down appetite and cravings, and signals through the vagus nerve reinforce the sense of being full sooner.
- It slows the stomach. By delaying how quickly food leaves the stomach, GLP-1 keeps you feeling satisfied for longer after a meal.
- It steadies blood sugar. It prompts the pancreas to release insulin, but only when blood glucose is high — a “glucose-dependent” action that keeps the risk of low blood sugar low. It also suppresses glucagon, a hormone that would otherwise push the liver to release more glucose.
Where the second hormone comes in
Tirzepatide’s distinguishing feature is that it also activates the receptor for a second incretin, GIP (glucose-dependent insulinotropic polypeptide). GIP further enhances insulin release after meals and acts directly on fat tissue. The two mechanisms appear to work synergistically — together producing greater weight loss than either could achieve alone — which is the leading explanation for why tirzepatide tends to outperform single-pathway GLP-1 medicines in direct comparisons.
There is a deeper reason these medicines can succeed where diets so often stall. When you lose weight by eating less, your body usually responds by ramping up appetite to claw the weight back — a biological pushback that undermines willpower. Drugs like tirzepatide blunt that response, effectively recalibrating the body’s hunger “setpoint” rather than relying on you to override it.
Mounjaro is a prescription medicine for managing obesity, not a lifestyle shortcut. It is designed to work with a reduced-calorie diet and more physical activity, under medical supervision — not instead of them.
What the clinical trials actually show
The evidence base for tirzepatide in weight management comes largely from Eli Lilly’s SURMOUNT trial programme, which enrolled over 5,000 people. The headline trial, SURMOUNT-1, studied adults with obesity who did not have type 2 diabetes over 72 weeks:
| Dose (weekly) | Average weight loss | Placebo |
|---|---|---|
| 5 mg | ~16.0% | 2.4% |
| 10 mg | ~21.4% | 2.4% |
| 15 mg | ~22.5% | 2.4% |
On the highest dose, around 4 in 5 participants lost at least 10% of their body weight, and roughly 2 in 5 lost 25% or more. When the 22.5% figure was published it was described as “unprecedented” for a weight-loss medicine — the highest ever reported in a pivotal trial of its kind. Importantly, body-composition analysis found that around three-quarters of the weight lost was fat mass.
Two caveats keep this honest. First, people with type 2 diabetes consistently lose less — in the SURMOUNT-2 trial, average reductions were several percentage points lower. Second, and most importantly, the results depend on continued treatment. A separate maintenance trial showed that people who stopped tirzepatide and switched to placebo regained a substantial share of their lost weight, while those who continued kept it off. Mounjaro manages weight; it does not permanently cure the biology behind it.
Who is it for — and who it is not for
Mounjaro is licensed for managing obesity, not for shedding a few pounds before an event. Prescribing is guided by NICE and generally starts from a BMI of 35 or above with at least one weight-related health condition — such as type 2 diabetes, high blood pressure, raised cholesterol, obstructive sleep apnoea or cardiovascular disease. Many private providers may consider a BMI from 30. Lower thresholds apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds, who can carry higher health risk at a lower BMI. In every case it is meant to be used alongside diet and activity changes, not on its own.
It is not suitable for everyone. It should not be used in pregnancy or while breastfeeding, or by people with a personal or family history of medullary thyroid cancer or the MEN2 syndrome, type 1 diabetes, or severe gastrointestinal disease. A prescriber will also weigh up conditions such as a history of pancreatitis. This is exactly why a proper clinical assessment — not a quick online form — matters.
Dosing and what to expect
Treatment starts low and builds slowly, which is deliberate — it gives the body time to adjust and limits side effects. The usual pattern begins at 2.5 mg once weekly, stepping up roughly every four weeks through 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to a maximum of 15 mg, guided by tolerance and response. Prescribing guidance suggests reviewing progress after around six months on the highest tolerated dose; if someone has not lost a meaningful amount of weight, the prescriber should reconsider whether to continue.
Side effects and safety
The most common side effects are gastrointestinal and tend to appear or worsen when the dose steps up. Nausea is the most frequent, reported by around a third of people on the top dose in trials, followed by diarrhoea, vomiting, constipation and burping. Reassuringly, most people find these mild and temporary — roughly 3 in 4 experience no nausea or only manageable symptoms — and they usually settle once the dose stabilises.
Rarer but more serious risks exist and are part of why medical oversight is essential. They include pancreatitis, an increased chance of gallstones (a known consequence of rapid weight loss generally), a small rise in resting heart rate, and low blood sugar if the medicine is combined with certain other diabetes drugs such as insulin or sulfonylureas. There is also a precautionary warning against use in people with a history of medullary thyroid cancer. Anyone experiencing severe or persistent abdominal pain should seek medical advice promptly.
The aesthetic side effects people ask about
Because weight can come off quickly, some effects are more visible than clinical. Rapid fat loss in the face can leave it looking gaunt — the phenomenon nicknamed “Mounjaro face” — and some people notice loose skin on the abdomen, arms or thighs, or temporary hair shedding. A particularly important one is muscle loss: roughly a quarter of the weight lost tends to be lean tissue, including muscle. This is why clinicians increasingly recommend eating enough protein and doing regular resistance exercise while on treatment, to protect muscle and strength.
How Mounjaro is accessed in the UK
Because it is a prescription-only medicine, Mounjaro can only be supplied lawfully by a regulated prescriber and pharmacy after an assessment. NHS access is real but very limited: it is being rolled out in phases through specialist weight-management services and, gradually, some GP prescribing, with strict BMI and comorbidity criteria. Only a small fraction of those who are medically eligible currently receive it this way, and full rollout is expected to take years. As a result, most people who take Mounjaro do so privately, typically paying somewhere in the region of £150–£300 or more per month depending on dose and provider, with prices having risen recently.
That gap between demand and supply has a darker side worth flagging plainly. The MHRA has warned about counterfeit and illegally sold weight-loss pens circulating online and through social media. Buying from an unregulated seller means no assessment, no monitoring, and a genuine risk of fake, contaminated or wrongly dosed products. If a deal looks cheap and effortless, that is precisely the warning sign.
Making an informed choice
Mounjaro is a genuinely significant medicine — the most effective weight-loss injection currently licensed in the UK, and a real option for people living with obesity when used properly, under medical care, alongside changes to diet and activity. But it is not a shortcut, it is not risk-free, and its benefits generally last only as long as treatment does. Realistic expectations and proper clinical oversight matter more than any headline percentage.
If you are weighing up your options, it is worth understanding how the different injections compare in our guide to the difference between Ozempic, Wegovy and Mounjaro, what actually happens in the first 12 weeks of weight-loss injections, and how the profession views the question of whether weight-loss injections are safe.
Whatever route you consider, choose care over convenience. Use Clinic Finder to compare accredited clinics and check that any prescriber you speak to is properly qualified and regulated, so that any decision about a medicine like Mounjaro is made with a real clinician who can assess your health — never bought blind from an unverified website.
